Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: Predictors of long-term outcome

International Journal of Clinical Practice

Volumn 61, Issue 5, 2007, Pages 748-756

  Boriani, G ^a   Diemberger, I ^a   Biffi, M ^a   Domenichini, G ^a   Martignani, C ^a   Valzania, C ^a   Branzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ADULT; ARTICLE; CARDIOVERSION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; LOADING DRUG DOSE; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RELAPSE; RISK ASSESSMENT; SINUS RHYTHM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ATRIAL FIBRILLATION; ATRIAL FLUTTER; DISEASE-FREE SURVIVAL; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 34247110336     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01298.x     Document Type: Article

References (37)

1. Waktare JE, Camm AJ. Acute treatment of atrial fibrillation: why and when to maintain sinus rhythm. Am J Cardiol 1998; 81: 3C-15C.
2. Silverman ME. History and personal observations of electrical cardioversion of atrial fibrillation. Am J Cardiol 2004; 94: 751-2.
3. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
4. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.
5. Zimetbaum P, Josephson ME. Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Ann Intern Med 2004; 141: 720-6.
6. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22: 1852-923.
7. Frick M, Frykman V, Jensen-Urstad M et al. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001; 24: 238-44.
8. Lehto M, Kala R. Persistent atrial fibrillation: a population based study of patients with their first cardioversion. Int J Cardiol 2003; 92: 145-50.
9. Okcun B, Yigit Z, Kucukoglu MS et al. Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial fibrillation. Echocardiography 2002; 19: 351-7.
10. Van Gelder IC, Crijns HJ, Van Gilst WH et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-6.
11. Lundstrom T, Ryden L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand 1988; 223: 53-9.
12. Nieuwlaat R, Capucci A, Camm A et al. Atrial fibrillation management: a prospective survey in ESC Member Countries The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-34.
13. Gallagher MM, Camm AJ. Classification of atrial fibrillation. Pacing Clin Electrophysiol 1997; 20: 1603-5.
14. Boriani G, Capucci A, Lenzi T et al. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 1995; 108: 355-8.
15. Capucci A, Boriani G, Rubino I et al. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994; 43: 305-13.
16. Gustafsson C, Asplund K, Britton M et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1445-6.
17. Prystowsky EN, Benson DW Jr, Fuster V et al. Management of patients with atrial fibrillation. A statement for healthcare professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-77.
18. Ewy GA. Optimal technique for electrical cardioversion of atrial fibrillation. Circulation 1992; 86: 1645-7.
19. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.
20. Van Gelder IC, Crijns HJ, Tieleman RG et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156: 2585-92.
21. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians, 2006.
22. Boriani G, Biffi M, Diemberger I et al. Rate control in atrial fibrillation: choice of treatment and assessment of efficacy. Drugs 2003; 63: 1489-509.
23. Chung MK. Randomized trials of rate vs. rhythm control for atrial fibrillation. J Interv Card Electrophysiol 2004; 10: 45-53.
24. Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-13.
25. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet 2006; 367: 262-72.
26. Vikman S, TH M, Yli-Mayry S et al. Heart rate variability and recurrence of atrial fibrillation after electrical cardioversion. Ann Med 2003; 35: 36-42.
27. Omran H, Jung W, Schimpf R et al. Echocardiographic parameters for predicting maintenance of sinus rhythm after internal atrial defibrillation. Am J Cardiol 1998; 81: 1446-9.
28. Barbaro V, Bartolini P, Calcagnini G et al. Effect of atrial fibrillation organization on internal defibrillation threshold. Ann Ist Super Sanita 2001; 37: 377-81.
29. Kirchhof P, Borggrefe M, Breithardt G. Effect of electrode position on the outcome of cardioversion. Card Electrophysiol Rev 2003; 7: 292-6.
30. Joglar JA, Kowal RC. Electrical cardioversion of atrial fibrillation. Cardiol Clin 2004; 22: 101-11.
31. Duytschaever M, Haerynck F, Tavernier R et al. Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. Pacing Clin Electrophysiol 1998; 21: 284-7.
32. Curtis AB, Seals AA, Safford RE et al. Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study. Am Heart J 2005; 1492: 304-8.
33. Naccarelli GV, Wolbrette DL, Bhatta L et al. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. J Interv Card Electrophysiol 2003; 9: 215-22.
34. VanGelder IC, Tuinenburg AE, Schoonderwoerd BS et al. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol 1999; 84: 147R-51R.
35. Elesber A, Rosales A, Herges R et al. Relapse and mortality following cardioversion of new-onset vs. recurrent atrial fibrillation and atrial flutter in the elderly. EHJ 2006; 27: 854-60.
36. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol 2003; 42: 1493-531.
37. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385-94.